Literature DB >> 9331082

Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes.

S Ren1, J S Yang, T F Kalhorn, J T Slattery.   

Abstract

We have investigated the formation of 4-hydroxycyclophosphamide (HCY) and deschloroethylcyclophosphamide (DCCY) from cyclophosphamide (CY) in human liver microsomes. For HCY, the estimated values (mean +/- SD; n = 3) of Km1 and Km2 were 0.095 +/- 0.072 and 5.09 +/- 4.30 mM, and the estimated values of Vmax1 and Vmax2 were 0.138 +/- 0.070 and 1.55 +/- 0.50 nmol/min/mg protein. For DCCY, Km1 and Km2 were 0.046 +/- 0.017 and 8.58 +/- 5.84 mM, and Vmax1 and Vmax2 were 0.006 +/- 0.003 and 0.274 +/- 0.214 nmol/min/mg protein. At CY concentrations of 0.1, 0.7, and 5 mM, HCY respectively accounted for 95.7 +/- 1.3, 95.1 +/- 2.4, and 90.7 +/- 2.7% of the total products of CY (HCY + DCCY; n = 6). In a separate experiment, 98.7 +/- 11.9% (n = 3) of CY loss could be accounted for by the formation of HCY at 0.1 mM CY. On the basis of cytochrome P450 (CYP) isoform-specific chemical inhibitor and cDNA-expressed human P450 isozyme studies, CYP2C9 and CYP3A4/5 seemed to be the major P450 isoforms responsible for HCY formation at low (0.1 mM) and high (0.7 and 5 mM) concentrations of CY, respectively. Although orphenadrine inhibition was observed in human liver microsomes (which has been taken to indicate CYP2B6 catalysis), orphenadrine inhibited cDNA-expressed CYP3A4 formation of HCY to the same extent observed in human liver microsomes, and the addition of orphenadrine to incubations containing sulfaphenazole (a specific inhibitor of CYP2C9) or troleandomycin (a specific CYP3A inhibitor) did not increase inhibition beyond that observed with sulfaphenazole or troleandomycin alone. Similar studies indicated that CYP3A4/5 was the major P450 isoform responsible for DCCY formation at high (0.7 and 5 mM) concentrations of CY. The P450 isoform responsible for DCCY formation at 0.1 mM CY could not be identified due to its very low formation rate.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9331082

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 2.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

Review 3.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

Review 4.  Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors:  Bertrand Rochat
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.

Authors:  Nasir Ali Afsar; Mike Ufer; Sierk Haenisch; Cornelia Remmler; Ahmed Mateen; Ahmed Usman; Khwaja Zafar Ahmed; Hakimuddin Razi Ahmad; Ingolf Cascorbi
Journal:  Eur J Clin Pharmacol       Date:  2011-10-20       Impact factor: 2.953

6.  Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics.

Authors:  Dominique A Ramirez; Keagan P Collins; Allister E Aradi; Katherine A Conger; Daniel L Gustafson
Journal:  Drug Metab Dispos       Date:  2018-12-19       Impact factor: 3.922

7.  Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

Authors:  Laimonas Griskevicius; Umit Yasar; Mia Sandberg; Mats Hidestrand; Erik Eliasson; Gunnel Tybring; Moustapha Hassan; Marja-Liisa Dahl
Journal:  Eur J Clin Pharmacol       Date:  2003-04-09       Impact factor: 2.953

Review 8.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

9.  Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

Authors:  A D Huitema; R A Mathôt; M M Tibben; J H Schellens; S Rodenhuis; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

10.  Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation.

Authors:  In-Wha Kim; Hwi-yeol Yun; Boyoon Choi; Nayoung Han; Myeong Gyu Kim; Seonyang Park; Jung Mi Oh
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.